Role of plasma bactericidal/permeability-increasing protein, group IIA phospholipase A2, C-reactive protein, and white blood cell count in the early detection of severe sepsis in the emergency department

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 9, 2012, Pages 697-704

  Uusitalo Seppälä, Raija ^a   Peuravuori, Heikki ^b   Koskinen, Pertti ^b,c   Vahlberg, Tero ^b   Rintala, Esa M ^a  

^a SATAKUNTA CENTRAL HOSPITAL   (Finland)

^b TURKU UNIVERSITY   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bactericidal permeability increasing protein; Group IIA phospholipase A2; Severe sepsis

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; C REACTIVE PROTEIN; GROUP 2A PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP II; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; BLOOD SAMPLING; CELL COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; FLUOROIMMUNOASSAY; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK; SEPSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TURBIDIMETRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; EMERGENCY SERVICE, HOSPITAL; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ROC CURVE; SEPSIS;

EID: 84865313399     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.677061     Document Type: Article

References (39)

1. Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, et al. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003;168:77-84. (Pubitemid 37046636)
2. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-51. (Pubitemid 38010630)
3. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420:885-91. (Pubitemid 36019643)
4. Hotchkiss RS, Tinsley KW, Karl IE. Role of apoptotic cell death in sepsis. Scand J Infect Dis 2003;35:585-92. (Pubitemid 37336877)
5. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med 2003;254:197-215. (Pubitemid 37070221)
6. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-95. (Pubitemid 34100944)
7. Vadas P, Pruzanski W. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock 1993;39:160-7. (Pubitemid 23057755)
8. Fourcade O, Simon MF, Viode C, Rugani N, Leballe F, Ragab A, et al. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995;80:919-27.
9. Pruzanski W, Vadas P. Phospholipase A2 - a mediator between proximal and distal effectors of inflammation. Immunol Today 1991;12:143-6.
10. Wiese A, Brandenburg K, Carroll SF, Rietschel ET, Seydel U. Mechanisms of action of bactericidal/permeability-increasing protein BPI on reconstituted outer membranes of Gram-negative bacteria. Biochemistry 1997;36:10311-9. (Pubitemid 27357743)
11. Madsen LM, Inada M, Weiss J. Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli. Infect Immun 1996;64:2425-30. (Pubitemid 26226800)
12. Ogawa M, Arakawa H, Yamashita S, Sakamoto K, Ikei S. Postoperative elevations of serum interleukin 6 and group II phospholipase A2: group II phospholipase A2 in serum is an acute phase reactant. Res Commun Chem Pathol Pharmacol 1992;75:109-15.
13. Berkestedt I, Herwald H, Ljunggren L, Nelson A, Bodelsson M. Elevated plasma levels of antimicrobial polypeptides in patients with severe sepsis. J Innate Immun 2010;2:478-82.
14. Calvano SE, Thompson WA, Marra MN, Coyle SM, de Riesthal HF, Trousdale RK, et al. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability- increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg 1994;129:220-6. (Pubitemid 24056079)
15. Rintala E, Peuravuori H, Pulkki K, Voipio-Pulkki LM, Nevalainen T. Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome. Intensive Care Med 2000;26:1248-51.
16. Uusitalo-Seppälä R, Koskinen P, Leino A, Peuravuori H, Vahlberg T, Rintala EM. Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6. Scand J Infect Dis 2011;43:883-90.
17. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/ SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
18. Nevalainen TJ, Kortesuo PT, Rintala E, Marki F. Immunochemical detection of group I and group II phospholipases A2 in human serum. Clin Chem 1992;38:1824-9.
19. Nupponen I, Turunen R, Nevalainen T, Peuravuori H, Pohjavuori M, Repo H, Andersson S. Extracellular release of bactericidal/permeability-increasing protein in newborn infants. Pediatr Res 2002;51:670-4. (Pubitemid 34547327)
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
21. Gronroos JO, Laine VJ, Nevalainen TJ. Bactericidal group IIA phospholipase A2 in serum of patients with bacterial infections. J Infect Dis 2002;185:1767-72. (Pubitemid 34615471)
22. von der Mohlen MA, van der Poll T, Jansen J, Levi M, van Deventer SJ. Release of bactericidal/permeability-increasing protein in experimental endotoxemia and clinical sepsis. Role of tumor necrosis factor. J Immunol 1996;156:4969-73. (Pubitemid 26174487)
23. Vadas P, Browning J, Edelson J, Pruzanski W. Extracellular phospholipase A2 expression and infl ammation: the relationship with associated disease states. J Lipid Mediat 1993;8:1-30. (Pubitemid 23265461)
24. Green JA, Smith GM, Buchta R, Lee R, Ho KY, Rajkovic IA, Scott KF. Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation 1991;15:355-67.
25. Haapamäki MM, Grönroos JM, Nurmi H, Alanen K, Nevalainen TJ. Gene expression of group II phospholipase A2 in intestine in Crohn 's disease. Am J Gastroenterol 1999; 94:713-20. (Pubitemid 29124871)
26. Elsbach P, Weiss J, Franson RC, Beckerdite-Quagliata S, Schneider A, Harris L. Separation and purification of a potent bactericidal/permeability- increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J Biol Chem 1979;254:11000-9. (Pubitemid 10163285)
27. Foreman-Wykert AK, Weinrauch Y, Elsbach P, Weiss J. Cellwall determinants of the bactericidal action of group IIA phospholipase A2 against Gram-positive bacteria. J Clin Invest 1999;103:715-21. (Pubitemid 29122425)
28. Grönroos JO, Salonen JH, Viander M, Nevalainen TJ, Laine VJ. Roles of group IIA phospholipase A2 and complement in killing of bacteria by acute phase serum. Scand J Immunol 2005;62:413-9. (Pubitemid 41565395)
29. Elsbach P. Bactericidal permeability-increasing protein in host defence against Gram-negative bacteria and endotoxin. Ciba Found Symp 1994;186:176-87; discussion 187-189.
30. Weiss J, Inada M, Elsbach P, Crowl RM. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J Biol Chem 1994;269: 26331-7. (Pubitemid 24328451)
31. Grönroos JM, Kuttila K, Nevalainen TJ. Group II phospholipase A2 in serum in critically ill surgical patients. Crit Care Med 1994;22:956-9. (Pubitemid 24182726)
32. Rintala EM, Aittoniemi J, Laine S, Nevalainen TJ, Nikoskelainen J. Early identifi cation of bacteremia by biochemical markers of systemic infl ammation. Scand J Clin Lab Invest 2001;61:523-30. (Pubitemid 33702359)
33. Dajak M, Ignjatovic S, Majkic-Singh N, Lausevic Z, Bukumirovic V. Prognostic value of phospholipase A2 group II, C-reactive protein and Simplified Acute Physiological Score II in intensive care patients. Clin Lab 2006;52: 387-92. (Pubitemid 44336221)
34. Weiss J, Elsbach P, Olsson I, Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978;253:2664-72. (Pubitemid 8328425)
35. Gullberg U, Andersson E, Garwicz D, Lindmark A, Olsson I. Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. Eur J Haematol 1997;58:137-53. (Pubitemid 27183463)
36. Schultz H, Hume J, Zhang de S, Gioannini TL, Weiss JP. A novel role for the bactericidal/permeability increasing protein in interactions of Gram-negative bacterial outer membrane blebs with dendritic cells. J Immunol 2007;179: 2477-84.
37. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW. Bactericidal/permeability-increasing protein has endotoxinneutralizing activity. J Immunol 1990;144:662-6. (Pubitemid 20036099)
38. Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest 1990;85: 853-60. (Pubitemid 20087489)
39. Karlsson S, Varpula M, Ruokonen E, Pettilä V, Parviainen I, Ala-Kokko TI, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007;33: 435-43. (Pubitemid 46333839)